A double‐blind, placebo‐controlled pilot study of ondansetron for patients with obsessive‐compulsive disorder
The DOI matches its Crossref record.
Abstract
Objective: To assess the efficacy and tolerability of ondansetron in combination with selective serotonin reuptake inhibitors (SSRIs) in patients with obsessive‐compulsive disorder (OCD). Methods: The study was an 8‐week pilot double‐blind randomized clinical trial. Forty‐two adult outpatients who met the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM‐IV‐TR) criteria for OCD based on the structured clinical interview participated in the trial. In this study, patients were randomly assigned to receive either ondansetron (4 mg) plus fluoxetine or fluoxetine (20 mg/day) plus placebo. Results: The results showed a significant difference between two groups in the treatment of OCD (based on t ‐test). There was not any significant difference between the two groups in terms of observed side effects. Conclusions: The results of this study show that ondansetron has positive effects on obsession and compulsion which start two weeks after the beginning of the treatment. Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“The findings of small randomised placebocontrolled augmentation studies with 5-HT3 antagonists provide evidence for the efficacy of the addition of ondansetron to fluoxetine [I (PCT)] (Soltani et al., 2010) and for the addition of granisetron to fluvoxamine [I (PCT)] (Askari et al., 2012).”
BackgroundEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C., & Bloch, M. H. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.05.006 · Cited by 222
“The studies showing the clearest effects are again from Iran [57, 58].”
BackgroundDold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Pharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Fineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
“Australian & New Zealand Journal of Psychiatry, 47(2) ondansetron was explored in an 8-week, double-blind, placebo-controlled pilot study (n = 42) (Soltani et al., 2010) in which patients were randomised to receive either fluoxetine (20 mg/day) and ondansetron (4 mg/day) or fluoxetine (20 mg/day) and placebo.”
BackgroundA 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder
Stein, D. J., Koen, N., Fineberg, N., Fontenelle, L. F., Matsunaga, H., Osser, D., & Simpson, H. B. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0268-9 · Cited by 65
Heidari, M., Zarei, M., Hosseini, S. M. R., Taghvaei, R., Maleki, H., Tabrizi, M., Fallah, J., & Akhondzadeh, S. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000043 · Cited by 48
Pallanti, S., Bernardi, S., Antonini, S., Singh, N., & Hollander, E. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.003 · Cited by 42
High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions
Stern, E. R., Shahab, R., Grimaldi, S. J., Leibu, E., Murrough, J. W., Fleysher, L., Parides, M. K., Coffey, B. J., Burdick, K. E., & Goodman, W. K. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0174-x · Cited by 27
Corrêa Filho, J. M., & Baltieri, D. A. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.12.018 · Cited by 26
Andrade, C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14f09704 · Cited by 14
Metadata
- Authors
- Soltani, F., Sayyah, M., Feizy, F., Malayeri, A., Siahpoosh, A., & Motlagh, I.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2010-08
- Volume
- 25
- Issue
- 6
- Pages
- 509-513
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2059738728
- Cited by
- 78
- References
- 0
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.